CClinicalTrials.gg
TerminatedNCT04277936Updated Aug 5, 2021Results posted

Pharmacologic Modulation of Hippocampal Activity in Psychosis

A Phase 2 interventional study of Levetiracetam 500 mg in Schizophrenia; Psychosis, sponsored by Vanderbilt University Medical Center. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-05.

Sponsored by Vanderbilt University Medical Center · Phase 2, Interventional, and Basic science

Why this study was terminated
Study was redesigned and submitted as a new protocol (NCT04559529).
Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to test whether administration of levetiracetam (LEV), a commonly used anti-epileptic that alters neurotransmitter release, can reduce hippocampal hyperactivity. Specifically, we will utilize two functional magnetic resonance imaging (MRI) techniques: 1) blood oxygen level dependence (BOLD) contrast will assess activity with a visual scene processing task that engages the anterior hippocampus and 2) arterial spin labeling (ASL) will assess baseline activity. This study will also assess whether patients have improvement in their symptoms after receiving LEV. Previous studies in people with psychotic disorders have shown that the hippocampus is hyperactive and more activity correlates with worsening of clinical symptoms. Therefore, the aim of this study is to use an intervention to further understand the underlying mechanisms of the hippocampus in psychosis.

02

Conditions studied

  • Schizophrenia; Psychosis

Keywords

  • Hippocampus
03

In context

Schizophrenia

3,471 studies on the registry are indexed under Schizophrenia; 471 are open to participants now.

This study's enrollment of 1 is below the median of 70 across 2,871 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

Vanderbilt University Medical Center is the lead sponsor of 824 studies on the registry; 164 are open to participants now.

Of its 122 completed or terminated interventional studies of FDA-regulated products, 91 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria for psychosis subjects:

  1. Men and women age 18 - 65.
  2. Communicative in English.
  3. Provide voluntary, written informed consent.
  4. Physically healthy by medical history.
  5. BMI > 17.5 and \< 45.
  6. Diagnosis of a psychotic disorder confirmed by Structured Clinical Interview for DSM-V (SCID) or diagnostic interview with a trained clinician.
  7. Stable medication regimen over at least the past two weeks, including the use of either an oral or intramuscular administration of an antipsychotic medication.
  8. For females, no longer of child-bearing potential, or agreeing to practice effective contraception during the study; and,
  9. For females of child-bearing potential, must have negative urine pregnancy test at time of screening visit and before each testing day.
  10. Not breastfeeding/nursing at time of screening or at any time during the study.

Inclusion criteria for healthy controls All of the above except for subjects will be psychiatrically healthy and not taking psychotropic or potentially psychoactive prescription medication.

Exclusion criteria for psychosis subjects

  1. Age less than 18 or greater than 65.
  2. Not communicative in English.
  3. Unable to provide written informed consent.
  4. Current medical or neurological illness.
  5. History of severe head trauma.
  6. BMI \< 17.5 or > 45.
  7. Meets criteria for diagnosis of substance or alcohol use disorder within the past month.
  8. Positive urine pregnancy test at time of screening, before each testing day, or any potential concern for pregnancy at any time during the study.
  9. Breastfeeding/nursing at time of screening or at any time during the study.
  10. Conditions that preclude MR scanning
  11. Conditions that preclude study drug administration

Exclusion criteria for healthy controls

All of the above and in addition:

  1. Current use of psychotropic or potentially psychoactive prescription medication.
  2. Major psychiatric disorder as determined by DSM-V (major depression, bipolar disorder, obsessive compulsive disorder, post-traumatic stress disorder, etc)
05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Levetiracetam (LEV) 500 mg

    Participants will take their first dose of 500 mg LEV. After a two hour time window, the participants will complete MRI study. After MRI, patients will begin a 2-week intervention with 250 mg BID oral LEV.

    Drug: Levetiracetam 500 mg

Interventions

  • DrugLevetiracetam 500 mg

    Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the hippocampus.

    Also known as: Keppra

06

What researchers measure

Primary outcomes

  1. Hippocampal Activity (Arterial Spin Labeling [ASL] Study)

    Change in ASL signal after drug administration

    Time frame: 2 hours and 2 weeks after administration

  2. Hippocampal Recruitment (BOLD Study)

    Change in BOLD signal after drug administration

    Time frame: 2 hours and 2 weeks after administration

Secondary outcomes

  1. Cognitive Symptoms

    Change in eye-tracking relational memory task

    Time frame: 2 weeks after administration

  2. Positive and Negative Symptoms

    Change PANSS score

    Time frame: 2 weeks after administration

07

Results

Posted Aug 5, 2021

Participant flow

Participant flow — Overall Study
MilestoneLevetiracetam (LEV) 500 mg
Started1
Completed1
Not completed0

Outcome measures

PrimaryHippocampal Activity (Arterial Spin Labeling [ASL] Study)

Change in ASL signal after drug administration

Time frame:
2 hours and 2 weeks after administration

No measurements were reported for this outcome.

PrimaryHippocampal Recruitment (BOLD Study)

Change in BOLD signal after drug administration

Time frame:
2 hours and 2 weeks after administration

No measurements were reported for this outcome.

SecondaryCognitive Symptoms

Change in eye-tracking relational memory task

Time frame:
2 weeks after administration

No measurements were reported for this outcome.

SecondaryPositive and Negative Symptoms

Change PANSS score

Time frame:
2 weeks after administration

No measurements were reported for this outcome.

Adverse events

Collected over 2 weeks The protocol is: a) single dose of 500mg LEV, b) neuroimaging session #1, c) 500mg LEV for 2-weeks and d) imaging session #2. This participant only took a single 500mg dose and never advanced to the protocol components c) and d), i.e. did not complete the study protocol. 93% of LEV is cleared in 48 hours, so monitoring is not necessary beyond 1 week.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levetiracetam (LEV) 500 mg0/1 (0%)0/1 (0%)0/1 (0%)

Baseline characteristics

Data were collected for a single subject, but study design was changed and study was discontinued. No data were analyzed.

Age, Categorical
Age, CategoricalLevetiracetam (LEV) 500 mg
<=18 years—
Between 18 and 65 years—
>=65 years—
Age, Continuous
Age, ContinuousLevetiracetam (LEV) 500 mg
Sex: Female, Male
Sex: Female, MaleLevetiracetam (LEV) 500 mg
Female—
Male—
Race (NIH/OMB)
Race (NIH/OMB)Levetiracetam (LEV) 500 mg
American Indian or Alaska Native—
Asian—
Native Hawaiian or Other Pacific Islander—
Black or African American—
White—
More than one race—
Unknown or Not Reported—
Region of Enrollment
Region of Enrollment(participants)Levetiracetam (LEV) 500 mg
08

Study locations

1 site
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Feb 29, 2020
  • Informed consent form · Feb 29, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04277936
Lead sponsor
Vanderbilt University Medical Center
Responsible party
Stephan Heckers (Department Chair, Vanderbilt University Medical Center) — Principal investigator
First posted
Feb 20, 2020
Start date
May 11, 2020
Primary completion
Aug 31, 2020
Completion
Aug 31, 2020
Results posted
Aug 5, 2021
Last update
Aug 5, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion